APA

Filip S., Vanásek J., Bláha M., Mericka P., Vávrová J. & Podzimek K. (20000110). The increase of the rate of hemopoietic recovery and clinical benefit of the erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) with peripheral blood progenitor cells (PBPC) after intensive cyclic chemotherapy in high-risk breast cancer patients. : Neoplasma.

Chicago

Filip S, Vanásek J, Bláha M, Mericka P, Vávrová J and Podzimek K. 20000110. The increase of the rate of hemopoietic recovery and clinical benefit of the erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) with peripheral blood progenitor cells (PBPC) after intensive cyclic chemotherapy in high-risk breast cancer patients. : Neoplasma.

Harvard

Filip S., Vanásek J., Bláha M., Mericka P., Vávrová J. and Podzimek K. (20000110). The increase of the rate of hemopoietic recovery and clinical benefit of the erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) with peripheral blood progenitor cells (PBPC) after intensive cyclic chemotherapy in high-risk breast cancer patients. : Neoplasma.

MLA

Filip S, Vanásek J, Bláha M, Mericka P, Vávrová J and Podzimek K. The increase of the rate of hemopoietic recovery and clinical benefit of the erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) with peripheral blood progenitor cells (PBPC) after intensive cyclic chemotherapy in high-risk breast cancer patients. : Neoplasma. 20000110.